Evidence map›Paper›PMID 27034171›Full record

ArticleOncotarget2016

Rheb may complex with RASSF1A to coordinate Hippo and TOR signaling.

Nicholas Nelson, Geoffrey J Clark

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Tumor suppressor C-RASSF proteins.Cellular and molecular life sciences : CMLS · 2018
    Review
  7. Phosphorylated mTOR and YAP serve as prognostic markers and therapeutic targets in gliomas.Laboratory investigation; a journal of technical methods and pathology · 2017
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Nicholas NelsonDepartment of Biochemistry and Molecular Biology, University of Louisville, Louisville, KY, USA.
Geoffrey J ClarkDepartment of Biochemistry and Molecular Biology, University of Louisville, Louisville, KY, USA.
University of Louisville · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The TOR pathway is a vital component of cellular homeostasis that controls the synthesis of proteins, nucleic acids and lipids. Its core is the TOR kinase. Activation of the TOR pathway suppresses autophagy, which plays a vital but complex role in tumorigenesis. The TOR pathway is regulated by activation of the Ras-related protein Rheb, which can bind mTOR. The Hippo pathway is a major growth control module that regulates cell growth, differentiation and apoptosis. Its core consists of an MST/LATS kinase cascade that can be activated by the RASSF1A tumor suppressor. The TOR and Hippo pathways may be coordinately regulated to promote cellular homeostasis. However, the links between the pathways remain only partially understood. We now demonstrate that in addition to mTOR regulation, Rheb also impacts the Hippo pathway by forming a complex with RASSF1A. Using stable clones of two human lung tumor cell lines (NCI-H1792 and NCI-H1299) with shRNA-mediated silencing or ectopic overexpression of RASSF1A, we show that activated Rheb stimulates the Hippo pathway, but is suppressed in its ability to stimulate the TOR pathway. Moreover, by selectively labeling autophagic vacuoles we show that RASSF1A inhibits the ability of Rheb to suppress autophagy and enhance cell growth. Thus, we identify a new connection that impacts coordination of Hippo and TOR signaling. As RASSF1A expression is frequently lost in human tumors, the RASSF1A status of a tumor may impact not just its Hippo pathway status, but also its TOR pathway status.

Indexed as

Signal TransductionApoptosisAutophagyCell Line, TumorCell ProliferationGene Expression Regulation, EnzymologicGene Expression Regulation, NeoplasticHippo Signaling PathwayHumansLung NeoplasmsProtein BindingProtein Serine-Threonine KinasesRas Homolog Enriched in Brain ProteinRNA InterferenceTime FactorsTOR Serine-Threonine KinasesMTOR protein, humanProtein Serine-Threonine KinasesRas Homolog Enriched in Brain ProteinRASSF1 protein, humanRHEB protein, humanTOR Serine-Threonine KinasesTumor Suppressor ProteinsHippoRasRASSF1ARhebTOR

Identifiers

PMID27034171
PMCPMC5085121
OpenAlexW2317828769

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.